260 related articles for article (PubMed ID: 30339627)
1. A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
Kobayashi S; Nagano H; Tomokuni A; Gotoh K; Sakai D; Hatano E; Seo S; Terajima H; Uchida Y; Ajiki T; Satake H; Kamei K; Tohyama T; Hirose T; Ikai I; Morita S; Ioka T;
Ann Surg; 2019 Aug; 270(2):230-237. PubMed ID: 30339627
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study.
Kobayashi S; Nagano H; Sakai D; Eguchi H; Hatano E; Kanai M; Seo S; Taura K; Fujiwara Y; Ajiki T; Takemura S; Kubo S; Yanagimoto H; Toyokawa H; Tsuji A; Terajima H; Morita S; Ioka T
Cancer Chemother Pharmacol; 2014 Oct; 74(4):699-709. PubMed ID: 25074036
[TBL] [Abstract][Full Text] [Related]
3. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
Yanagimoto H; Toyokawa H; Sakai D; Wada H; Satoi S; Yamamoto T; Nagano H; Toyoda M; Ajiki T; Satake H; Tsuji A; Miyamoto A; Tsujie M; Takemura S; Yanagihara K; Ioka T
Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakamura H; Nakashima A; Sueda T
Ann Surg; 2009 Dec; 250(6):950-6. PubMed ID: 19953713
[TBL] [Abstract][Full Text] [Related]
5. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
Suzuki E; Ikeda M; Okusaka T; Nakamori S; Ohkawa S; Nagakawa T; Boku N; Yanagimoto H; Sato T; Furuse J
Cancer Chemother Pharmacol; 2013 May; 71(5):1141-6. PubMed ID: 23525694
[TBL] [Abstract][Full Text] [Related]
6. Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients.
Harada N; Shirabe K; Yoshizumi T; Ikegami T; Uchiyama H; Soejima Y; Yamashita Y; Saeki H; Oki E; Kawanaka H; Morita M; Ikeda T; Matsuura H; Okadome K; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):539-48. PubMed ID: 24693682
[TBL] [Abstract][Full Text] [Related]
7. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
Hosoda K; Fukushima K; Shimizu A; Motoyama H; Kubota K; Notake T; Sugenoya S; Hayashi H; Yasukawa K; Kobayashi R; Soejima Y
Oncology; 2021; 99(11):703-712. PubMed ID: 34515195
[TBL] [Abstract][Full Text] [Related]
9. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
[TBL] [Abstract][Full Text] [Related]
10. Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
Shimoda M; Kubota K; Shimizu T; Katoh M
Br J Surg; 2015 Jun; 102(7):746-54. PubMed ID: 25833230
[TBL] [Abstract][Full Text] [Related]
11. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures.
Takahara T; Nitta H; Hasegawa Y; Itou N; Takahashi M; Nishizuka S; Wakabayashi G
Cancer Chemother Pharmacol; 2012 May; 69(5):1127-33. PubMed ID: 22207029
[TBL] [Abstract][Full Text] [Related]
12. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Uesaka K; Boku N; Fukutomi A; Okamura Y; Konishi M; Matsumoto I; Kaneoka Y; Shimizu Y; Nakamori S; Sakamoto H; Morinaga S; Kainuma O; Imai K; Sata N; Hishinuma S; Ojima H; Yamaguchi R; Hirano S; Sudo T; Ohashi Y;
Lancet; 2016 Jul; 388(10041):248-57. PubMed ID: 27265347
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of S-1 Adjuvant Chemotherapy for Resected Biliary Tract Cancer: A Retrospective Propensity-Matched Analysis.
Yoshida M; Yanagimoto H; Tsugawa D; Akita M; Urade T; Nanno Y; Fukushima K; Gon H; Komatsu S; Asari S; Kido M; Toyama H; Ajiki T; Fukumoto T
Am Surg; 2024 Jun; 90(6):1279-1289. PubMed ID: 38226586
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
Takashima A; Morizane C; Ishii H; Nakamura K; Fukuda H; Okusaka T; Furuse J
Jpn J Clin Oncol; 2010 Dec; 40(12):1189-91. PubMed ID: 20630899
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Ito Y; Sasahira N; Hirano K; Tsujino T; Toda N; Tada M; Omata M; Koike K
Invest New Drugs; 2012 Apr; 30(2):708-13. PubMed ID: 20924641
[TBL] [Abstract][Full Text] [Related]
17. A feasibility study of gemcitabine, S-1 and leucovorin combination therapy (GSL) for advanced biliary tract cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Tada M; Koike K
J Chemother; 2019 Sep; 31(5):284-289. PubMed ID: 31179889
[No Abstract] [Full Text] [Related]
18. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).
Morizane C; Okusaka T; Mizusawa J; Takashima A; Ueno M; Ikeda M; Hamamoto Y; Ishii H; Boku N; Furuse J
Cancer Sci; 2013 Sep; 104(9):1211-6. PubMed ID: 23763511
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of gemcitabine, cisplatin, and S-1 combination therapy for patients with untreated advanced biliary tract cancer.
Moriwaki T; Ishida H; Araki M; Endo S; Yoshida S; Kobayashi M; Hamano Y; Sugaya A; Shimoyamada M; Hasegawa N; Imanishi M; Ito Y; Sato D; Hyodo I
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):669-74. PubMed ID: 25877225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
